Pitch@Palace Applications Now Open

You may be aware that Pitch@Palace 9.0 applications are now open and we would like to encourage you to apply http://pitchatpalace.com/apply-9/

The programme offers mentoring and advice to those developing business ideas around data, intelligence and the future of security.

Whether you simply have an idea on paper or your business is at the point of scaling up Pitch@Palace 9.0 seeks to discover entrepreneurs and companies that have identified opportunities in the following areas:

  • Artificial Intelligence
  • Machine Learning
  • IoT
  • Cyber-security
  • Blockchain
  • Defence
  • Cloud
  • 3D Printing

Manchester Enterprise Centre, UMIP and Business Engagement at The University of Manchester are delighted to announce that HRH, The Duke of York, is bringing a key boot camp event in his Pitch@Palace initiative to our campus in March 2018.

Manchester has a long and important connection to the history of computing that cannot be overstated. This legacy continues in our city today through our teaching, research, spinout companies and local SMEs and corporates engaged in such future facing industries.

We wish to see as many of our companies represented at these events, to showcase the thriving technology, science and entrepreneurial communities in the Greater Manchester ecosystem. Applications are now open for interested entrepreneurs and we would like to encourage you to apply before the deadline of 15th February 2018.

Key dates for information:

31st January, 2018 Pitch@Palace On Tour London MOD (hosted by Rise)
2nd February, 2018 Pitch@Palace On Tour Cheltenham NCSC (hosted by Wayra GCHQ)
7th February, 2018 Pitch@Palace On Tour Huddersfield University of Huddersfield
13th March, 2018 Pitch@Palace Boot Camp The University of Manchester

For further information about the Pitch@Palace process visit http://www.pitchatpalace.com

New deal could bring first treatment for rare terminal disorder in children

Scientists from The University of Manchester believe children suffering from Sanfilippo – a rare terminal disorder that affects children’s brains – could be treated successfully for the first time. There are currently four types of Sanfilippo syndrome, Type A, B, C and D, which are caused by a lack of enzymes, which helps to break down and recycle long chain sugars and results in a build-up of sugars in the body and particularly the brain.

Sanfilippo Type B affects around one in 200,000 live births, whereas the most common of the four types, Sanfilippo Type A affects around one in 100,000 live births in the UK.Affected children suffer from hyperactivity, speech loss, profound mental disability and eventually lose the ability to walk, talk or eat.

Professor Brian Bigger

Prof Brian Bigger, Professor of Cell and Gene Therapy at The University of Manchester, said a stem cell gene therapy technology developed in his laboratory and recently published in the prestigious journal Brain1 and selected for Editor’s choice, will be used by Orchard Therapeutics to treat Sanfilippo syndrome Type B after the company recently acquired an exclusive licence.

Prof Bigger said: “UK-based clinical-stage biotechnology company Orchard Therapeutics is already a trusted collaborative partner and the acquisition of the licence for Sanfilippo Type B complements the existing collaboration program already in place for Sanfilippo Type A.

“We are very hopeful that this will be transformative for patients, and that this technology will change the lives of children with Sanfilippo Type A and Type B.
“As it stands the disease is incurable and people with Sanfilippo syndrome normally live until adolescence or early adulthood after suffering for many years.
“Children with Sanfilippo begin showing symptoms of hyperactivity, severe behavioural problems and miss development milestones as toddlers. Later they show symptoms similar to dementia with most never achieving a developmental age beyond two years.”

Dr Jesus Garcia-Segovia, Orchard’s VP Clinical Development, CNS and Metabolic Disorders commented: “The incorporation of Sanfilippo syndrome type B into our development pipeline is a significant milestone in the consolidation of our neurometabolic franchise, which is currently focused on the development of autologous ex-vivo haematopoietic stem-cell gene therapy for children suffering from Sanfilippo syndrome type A. We are very excited at the possibility of bringing effective treatments capable of addressing the high unmet medical need in children suffering from these devastating conditions.”

Furthermore, Prof Bigger said the stem cell gene therapy, if successful, could also lead to major breakthroughs in treatment of more common diseases.
“If this is successful we could be in line for treating more common diseases such as Parkinson and Alzheimer diseases.
“If we can show that it is possible to treat single gene brain diseases such as Sanfilippo with stem cell gene therapy, it will pave the way for other treatments.
“We are also grateful to The University of Manchester’s technology transfer company, UMI3 Ltd, for their role in negotiating the terms of this major deal with Orchard Therapeutics.”

1 https://academic.oup.com/brain/article-lookup/doi/10.1093/brain/awx311
DOI 10.1093/brain/awx311

SkinBioTherapeutics CEO, Cath O’Neill named as one of 50 Movers and Shakers in BioBusiness 2017 report

Manchester, UK – 2 November 2017 – SkinBioTherapeutics plc (AIM: SBTX, the “Company”), CEO Dr Cath O’Neill has been recognised as one of the top 50 female leaders in healthcare business in the UK as part of BioBusiness’ 2017 50 Movers and Shakers report.

The annual report published by BioBeat aims to celebrate exceptional female leaders and bioentrepreneurs who are driving innovative thinking within the UK healthcare industry making significant contributions to the success of the sector.

Dr O’Neill has been recognised for her research within the skin microbiome sector, work which resulted in her co-founding SkinBioTherapeutics, a life sciences company focusing on skin health.

SkinBioTherapeutics’ SkinBiotix® platform is based on lysate derived from probiotic bacteria and this technology is being applied to skin health. The Company has three programmes in development – in cosmetic skin care, anti-infection and skin repair – all multi-billion dollar markets.

In 2017, the Company has seen both financial and scientific success, having originally spun-out from The University of Manchester. In April 2017, it completed an IPO and was admitted to AIM raising £4.5m, and recently, its technology passed third party validated, cell toxicity tests. The Company is on track for its first programme to enter human trials in 2018.

Dr. Cath O’Neill, CEO of SkinBioTherapeutics, commented:

“I am honoured to be named as one of the UK’s leading women in the healthcare industry as part of the BioBeat 2017 report. The public recognition of women within the healthcare arena is important to encourage the next generation coming through.

“Developing a range of viable skin health products based on the SkinBiotix® technology is at the core of our business and I am proud of the results we have achieved so far. In the new arena of skin microbiome, our work is already attracting notice from the skin care industry. By driving forward our programmes, the result could be a range of products that could make a significant difference – not only to people with sensitive skin but also to healthcare professionals.”

The 2017 report has been released ahead of BioBeat’s event held at the Francis Crick Institute on Thursday 16 November 2017. This year’s event focuses on re-shaping biotech partnering to make a greater impact on health and wealth.

Boost for entrepreneurs and research commercialisation with £5m Northern Triangle Initiative

The University of Manchester is to lead a £5 million project which aims to transform the process of turning research into businesses across the North of England.

Announced today by the Universities Minister, Jo Johnson, the funding will see Manchester work with the Universities of Leeds and Sheffield to develop a ‘Northern Triangle Initiative’ (NTI).

The NTI will support the growth of a significantly enhanced, shared intellectual property pipeline, set up a unique regionally-focussed finance vehicle, seek to raise £350 million in private finance to support university commercialisation, and strengthen the entrepreneurial eco-system of the North of England.

In particular the award will allow the partners to collaborate in developing intellectual property projects into business propositions in areas of common strength such as advanced materials, medical technologies and computer science.

Clive Rowland, the CEO of UMI3 – The University of Manchester’s Innovation Group – said: “We will use this award to create a significant ‘Northern Triangle’ funding capability to create a positive collaborative climate and accelerate the amazing commercial potential of the research powerhouses at the universities of Manchester, Leeds and Sheffield.

“This funding, along with our existing investor partnerships, will help us overcome the continuing challenge of bridging the very risky stage between the laboratory and the market place, where developing prototypes is crucial to attracting venture funding.

“Very importantly, a key feature of this project is to enable us to develop more licensing proposals, which is a very effective way of translating science into business activities, but which has become somewhat a poor relation to the spin-out company route and is of less interest to entrepreneurs.”

The funding forms part of an allocation of £20 million to winners of the Higher Education Funding Council for England (HEFCE) Connecting Capability Fund competition and forms part of the Government’s Industrial Strategy green paper.

The Fund, which was announced in the Government’s Industrial Strategy green paper, supports universities in working together and with external partners to commercialise research, help deliver the Strategy and share good practice and capacity.

It was announced at the HEFCE conference in London where Deputy President and Vice-Chancellor of The University of Manchester, Professor Luke Georghiou was also speaking on ‘Universities as Core Partners in Realising the Industrial Strategy’.

Commenting on the award he said: “The University of Manchester is proud to be in the top two nationally for the value of our collaborative work with our business partners and always in the leading group for commercialisation of intellectual property through UMI3.

“This award helps to fill an important gap in the Northern regional innovation ecosystem and will enable us to step up our contribution to the economy alongside our partners in Leeds and Sheffield.”

Professor Lisa Roberts, Deputy Vice-Chancellor: Research and Innovation at the University of Leeds said: “This is a great opportunity to build on our formidable reputation in commercialisation.

“The Universities of Leeds, Manchester and Sheffield are three research powerhouses in the North, and by working together we will have significant impact on the commercialisation of our research.”

Professor John Derrick, Deputy Pro-Vice Chancellor for Research and Innovation at the University of Sheffield, said:

“The funding for the Northern Triangle Initiative lays the foundations for new advanced science and innovative industry collaborations that will help to deliver real change and create economic growth not only for the north but the whole of the UK.

“At Sheffield we are immensely proud of our longstanding research-industry links – particularly in advanced manufacturing – and we are looking forward to working with our partner institutions on this inspiring initiative extend these even further to bridge the gap between the outstanding research undertaken in universities and industry.”

The funding will last for three years and the immediate aims of the project are to work with investors and entrepreneurs to form a dynamic support system and initiate and develop some 75 technology transfer projects across the three partner universities.

  • Home